Jill Beggs, the Executive Vice President and CEO of Reinsurance at Everest Group, recently made a notable acquisition of shares in her company. According to a filing with the SEC, Beggs acquired 496 shares on October 1, 2026, at a price of $366.47 per share. This transaction reflects her ongoing commitment to the company and its strategic direction.
Beggs' acquisition is particularly significant as it comes at a time when the fire, marine, and casualty insurance industry is navigating various challenges and opportunities. Her investment may signal confidence in the company's future performance and stability within the sector.
Background
Everest Group, Ltd., identified by the SEC with Central Index Key (CIK) 0001095073, operates within the fire, marine, and casualty insurance industry (SIC code 6331). The company is publicly traded and has a fiscal year ending on December 31. The recent SEC filing, dated October 5, 2026, is one of several disclosures made by Beggs in recent months, indicating her active involvement in the company's financial activities.
What the Filing Says
The SEC filing reveals that Beggs acquired the shares to cover taxes on 969 vested restricted shares granted to her on September 11, 2025. The filing states, "Common Shares withheld to pay taxes on 969 vested restricted shares that were granted on 09/11/2025." Following this transaction, Beggs now owns a total of 7,817 shares in the company.
Impact
This acquisition may impact various stakeholders within the Everest Group and the broader insurance industry. For shareholders, Beggs' investment could be seen as a positive signal, potentially boosting confidence in the company's leadership and strategic direction. Additionally, it may influence employee morale and retention, as it demonstrates commitment from top executives.
What's Next
The filing does not say what happens next.
Read Next
Lee Chae Increases Stake in Magnachip Semiconductor Corp
Jamie Odell Reports Major Stock Transactions with Light & Wonder
Guiheen Lawrence P. Acquires 10,000 Shares of ADMA Biologics
Gilliam Joseph E reports significant stock transactions
ADMA Biologics CEO Grossman Reports Major Stock Transactions
Saba Capital Management reveals stock acquisitions in SEC filing









